title: Aminoglycoside cross-resistance in Mycobacterium tuberculosis due to mutations in the 5' untranslated region of whiB7.
abstract: Since the discovery of streptomycin's bactericidal activity against Mycobacterium tuberculosis, aminoglycosides have been utilized to treat tuberculosis (TB). Today, the aminoglycosides kanamycin and amikacin are used to treat multidrug-resistant (MDR) TB, and resistance to any of the second-line injectable antibiotics, including kanamycin, amikacin, or capreomycin, is a defining characteristic of extensively drug-resistant (XDR) TB. Resistance to kanamycin and streptomycin is thought to be due to the acquisition of unlinked chromosomal mutations. However, we identified eight independent mutations in the 5' untranslated region of the transcriptional activator whiB7 that confer low-level resistance to both aminoglycosides. The mutations lead to 23- to 145-fold increases in whiB7 transcripts and subsequent increased expression of both eis (Rv2416c) and tap (Rv1258c). Increased expression of eis confers kanamycin resistance in these mutants, while increased expression of tap, which encodes an efflux pump, is a previously uncharacterized mechanism of low-level streptomycin resistance. Additionally, high-level resistance to streptomycin arose at a much higher frequency in whiB7 mutants than in a wild-type (WT) strain. Although whiB7 is typically associated with intrinsic antibiotic resistance in M. tuberculosis, these data suggest that mutations in an uncharacterized regulatory region of whiB7 contribute to cross-resistance against clinically used second-line antibiotics. As drug resistance continues to develop and spread, understanding the mechanisms and molecular basis of antibiotic resistance is critical for the development of rapid molecular tests to diagnose drug-resistant TB strains and ultimately for designing regimens to treat drug-resistant cases of TB.
authors: Microbiology and Molecular Genetics Graduate Program, Department of Microbiology and Immunology, Emory University, Atlanta, Georgia, USA.
authors: Analise Z
authors: AZ
authors: Reeves
authors: Patricia J
authors: PJ
authors: Campbell
authors: Razvan
authors: R
authors: Sultana
authors: Seidu
authors: S
authors: Malik
authors: Megan
authors: M
authors: Murray
authors: Bonnie B
authors: BB
authors: Plikaytis
authors: Thomas M
authors: TM
authors: Shinnick
authors: James E
authors: JE
authors: Posey
mesh_terms: D020121:5' Untranslated Regions / Q000235:genetics*; D000617:Aminoglycosides / Q000494:pharmacology*; D000995:Antitubercular Agents / Q000494:pharmacology*; D001426:Bacterial Proteins / Q000235:genetics* / Q000378:metabolism; D016680:Genome, Bacterial / Q000235:genetics; D015151:Immunoblotting; D008826:Microbial Sensitivity Tests; D009154:Mutation; D009169:Mycobacterium tuberculosis / Q000187:drug effects / Q000235:genetics*; D018088:Tuberculosis, Multidrug-Resistant / Q000382:microbiology*
chemical_list: D020121:5' Untranslated Regions; D000617:Aminoglycosides; D000995:Antitubercular Agents; D001426:Bacterial Proteins
references: Nat Methods. 2009 Jan;6(1):67-9
references: 19079253
references: PLoS Pathog. 2010 Dec 16;6(12):e1001230
references: 21187903
references: Mol Microbiol. 2001 Nov;42(3):851-65
references: 11722747
references: Microb Pathog. 2009 Apr;46(4):185-93
references: 19272305
references: Br Med J. 1948 Oct 30;2(4582):769-82
references: 18890300
references: Antimicrob Agents Chemother. 2011 May;55(5):2032-41
references: 21300839
references: Antimicrob Agents Chemother. 2011 Jun;55(6):2515-22
references: 21444711
references: Genome Res. 2008 Nov;18(11):1851-8
references: 18714091
references: Microbiology (Reading). 2007 Feb;153(Pt 2):529-540
references: 17259625
references: Proc Natl Acad Sci U S A. 2005 Aug 23;102(34):12200-5
references: 16103351
references: Antimicrob Agents Chemother. 1998 May;42(5):1295-7
references: 9593173
references: J Biol Chem. 2007 Jun 29;282(26):18671-5
references: 17449476
references: Microbiology (Reading). 2002 Oct;148(Pt 10):3007-3017
references: 12368434
references: Cell. 2011 Apr 1;145(1):39-53
references: 21376383
references: J Clin Microbiol. 1998 May;36(5):1220-5
references: 9574680
references: PLoS One. 2012;7(7):e37516
references: 22829866
references: Microbiology (Reading). 2009 Apr;155(Pt 4):1272-1281
references: 19332828
references: Antimicrob Agents Chemother. 2005 Aug;49(8):3192-7
references: 16048924
references: Proc Natl Acad Sci U S A. 2009 Nov 24;106(47):20004-9
references: 19906990
references: Mol Microbiol. 2007 Feb;63(4):1096-106
references: 17238915
references: Antimicrob Agents Chemother. 2006 Aug;50(8):2836-41
references: 16870781
references: PLoS Pathog. 2009 Aug;5(8):e1000545
references: 19680450
references: Cell Host Microbe. 2007 Nov 15;2(5):352-64
references: 18005756
references: Antimicrob Agents Chemother. 2009 Aug;53(8):3181-9
references: 19451293
references: J Biol Chem. 2012 Jan 2;287(1):299-310
references: 22069311
references: Genome Res. 2009 Jul;19(7):1301-8
references: 19228590
references: Antimicrob Agents Chemother. 1996 Nov;40(11):2452-4
references: 8913445
references: J Bacteriol. 1998 Nov;180(22):5836-43
references: 9811639
references: Chem Rev. 2005 Feb;105(2):477-98
references: 15700953
references: Infection. 2004 Apr;32(2):109-11
references: 15057575
references: J Bacteriol. 1997 Aug;179(15):4795-801
references: 9244267
references: Microb Drug Resist. 2008 Mar;14(1):7-11
references: 18321205
references: Antimicrob Agents Chemother. 2008 Aug;52(8):2947-9
references: 18541729
references: J Clin Microbiol. 2010 Feb;48(2):402-11
references: 20032248